What Delisting Chinese Stocks from NYSE Means for Passive Funds
Though the situation is still fluid, recent developments have clarified the implications for investors.
Editor’s Note: Morningstar Direct users can access the full research report here.
On Monday, Jan. 11, 2021, the "Executive Order on Addressing the Threat from Securities Investments That Finance Communist Chinese Military Companies" signed by President Trump will become effective. In the past month, regulators have added more companies to the sanctioned list and issued some clarifications on the matter. Major international index providers completed their consultation processes and announced their plans. The major benchmark providers will exclude the securities listed by the Office of Foreign Assets Control, or OFAC, from their equity and fixed-income indexes. Any index funds and exchange-traded funds whose benchmarks will be excluding the affected securities will follow suit.
However, the interpretation of the executive order remains fluid. On Dec. 31, 2020, the New York Stock Exchange announced plans to delist the ADRs of three Chinese telecom companies. It put this on hold Jan. 4, 2021 but reverted to its original plan on Jan. 6. The latest guidance from the OFAC, issued on Jan. 6, explicitly stated three NYSE-listed ADRs and subsidiaries of the military companies were subject to the executive order. As such, we expect that international index providers will make further announcements in the days to come.
As it pertains to index-tracking products, irrespective of domicile (US and non-US), many funds tracking the affected indexes either have or are expected to follow the indexes' adjustments, depending on the effective dates of the changes for the relevant index. To comply with the latest OFAC guidance, US index funds and ETFs would likely have to sell their holdings in subsidiaries and ADRs not excluded by the relevant indexes. For index funds and ETFs domiciled in the US tracking an index that may not remove the securities listed in the OFAC list, we believe the managers will have to remove those securities, including the subsidiaries, before Jan. 11, 2021. In both cases, US index funds and ETFs will likely incur some additional tracking error to accommodate these exclusions.
Depending on their Chinese equity exposure, these stocks' weightings range from 0.04% in the case of the MSCI ACWI to 2.21% in the MSCI China A Index. To comply with the latest OFAC guidance, US index funds and ETFs would likely have to sell their holdings in other subsidiaries not excluded by the relevant indexes.
The situation remains fluid, and we estimate that the sanctioned companies aren't likely a significant portion of most investors' portfolios. Thus, the investment implications for many are likely immaterial. That said, it's important for investors to understand the potential impact and to incorporate new information as it comes to light.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.